JP2002544237A - 望ましい活性を有するプロテインａに基づく結合ドメイン - Google Patents

望ましい活性を有するプロテインａに基づく結合ドメイン

Info

Publication number
JP2002544237A
JP2002544237A JP2000617917A JP2000617917A JP2002544237A JP 2002544237 A JP2002544237 A JP 2002544237A JP 2000617917 A JP2000617917 A JP 2000617917A JP 2000617917 A JP2000617917 A JP 2000617917A JP 2002544237 A JP2002544237 A JP 2002544237A
Authority
JP
Japan
Prior art keywords
spa
variant
polypeptide
binding region
fab
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000617917A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002544237A5 (enExample
Inventor
シルバーマン，グレッグ・ジェイ
Original Assignee
ユニバーシティ オブ カリフォルニア，サン ディエゴ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニバーシティ オブ カリフォルニア，サン ディエゴ filed Critical ユニバーシティ オブ カリフォルニア，サン ディエゴ
Publication of JP2002544237A publication Critical patent/JP2002544237A/ja
Publication of JP2002544237A5 publication Critical patent/JP2002544237A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2000617917A 1999-05-15 2000-05-15 望ましい活性を有するプロテインａに基づく結合ドメイン Pending JP2002544237A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13438699P 1999-05-15 1999-05-15
US60/134,386 1999-05-15
PCT/US2000/013402 WO2000069457A1 (en) 1999-05-15 2000-05-15 Protein a based binding domains with desirable activities

Publications (2)

Publication Number Publication Date
JP2002544237A true JP2002544237A (ja) 2002-12-24
JP2002544237A5 JP2002544237A5 (enExample) 2007-07-12

Family

ID=22463140

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000617917A Pending JP2002544237A (ja) 1999-05-15 2000-05-15 望ましい活性を有するプロテインａに基づく結合ドメイン

Country Status (6)

Country Link
US (1) US20060205016A1 (enExample)
EP (2) EP1181052A4 (enExample)
JP (1) JP2002544237A (enExample)
AU (1) AU777005B2 (enExample)
CA (1) CA2374013A1 (enExample)
WO (1) WO2000069457A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010075175A (ja) * 2008-08-11 2010-04-08 Millipore Corp 改善された特異性を有する新規免疫グロブリン結合タンパク質
JP2013534532A (ja) * 2010-07-02 2013-09-05 ザ・ユニバーシティ・オブ・シカゴ プロテインＡ（ＳｐＡ）変種に関連する組成物および方法

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7211258B2 (en) 2002-04-10 2007-05-01 Protalex, Inc. Protein A compositions and methods of use
US7425331B2 (en) 2002-04-10 2008-09-16 Protalex, Inc. Protein A methods of use
JP5345539B2 (ja) 2006-09-29 2013-11-20 ジーイー・ヘルスケア・バイオ−サイエンシズ・アーベー 抗体単離のためのスタフィロコッカスアウレウス由来のドメインｃを含むクロマトグラフィーリガンド
ATE555128T1 (de) * 2006-11-30 2012-05-15 Res Dev Foundation Verbesserte immunglobulin-bibliotheken
WO2008127457A2 (en) 2006-12-06 2008-10-23 Repligen Corporation Nucleic acids encoding recombinant protein a
JP5626526B2 (ja) * 2008-09-25 2014-11-19 Jsr株式会社 アフィニティークロマトグラフィー用充填剤
SG162687A1 (en) 2008-12-24 2010-07-29 Millipore Corp Caustic stable chromatography ligands
WO2010110288A1 (ja) 2009-03-24 2010-09-30 株式会社カネカ 免疫グロブリンに親和性を有するタンパク質および免疫グロブリン結合性アフィニティーリガンド
SMT202000246T1 (it) * 2009-04-03 2020-07-08 Univ Chicago Composizioni e metodi relativi a varianti della proteina a (spa)
SG10201604554WA (en) 2011-06-08 2016-07-28 Emd Millipore Corp Chromatography matrices including novel staphylococcus aureus protein a based ligands
US9556281B2 (en) * 2011-08-15 2017-01-31 The University Of Chicago Compositions and methods related to antibodies to staphylococcal protein A
US20160074497A1 (en) * 2013-05-03 2016-03-17 The University Of Chicago Staphylococcus live cell vaccines
GB201506868D0 (en) * 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method for protein purification
WO2025036605A1 (en) * 2023-08-14 2025-02-20 Cytiva Bioprocess R&D Ab Vh3 binding separation matrix and methods for using the same

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8300693L (sv) * 1983-02-09 1984-08-10 Sven Lofdahl Sett att framstella och isolera proteiner och polypeptider samt en hybridvektor for detta
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US4879378A (en) 1989-03-30 1989-11-07 Union Carbide Chemicals And Plastics Company Inc. Polysiloxanes with pendant sterically hindered phenol moiety connected to the silicon atom via a carbonylyoxy-containing link
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5198531A (en) 1991-06-14 1993-03-30 Research Diagnostic Antibodies Polymeric resin for peptide synthesis
US5240680A (en) 1991-12-19 1993-08-31 Chiron Corporation Automated apparatus for use in peptide synthesis
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5891438A (en) * 1992-10-30 1999-04-06 The Regents Of The University Of California Method for stimulating production of variable region gene family restricted antibodies through B-cell superantigen vaccination
SE9400088D0 (sv) * 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
EP2258726A1 (en) 1995-06-14 2010-12-08 The Regents of the University of California High affinity human antibodies to c-erbB-2
US6031071A (en) 1996-01-24 2000-02-29 Biophage, Inc. Methods of generating novel peptides
WO1997036614A1 (en) * 1996-03-29 1997-10-09 Terman David S Polymerized staphylococcal protein a for treatment of diseases
US6013763A (en) * 1996-06-04 2000-01-11 Genentech, Inc. Peptide variants of protein A

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JPN6010013258, Ｍｏｌ．Ｉｍｍｕｎｏｌ．，１９９３，３０（１４），ｐ．１２７９−８５ *
JPN6010013259, Ｎａｔ．Ｂｉｏｔｅｃｈｎｏｌ．，１９９７，１５（８），ｐ．７７２−７ *
JPN6010013262, Ｊ．Ｉｍｍｕｎｏｌ．，１９９５，１５４（１２），ｐ．６４３７−４５ *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010075175A (ja) * 2008-08-11 2010-04-08 Millipore Corp 改善された特異性を有する新規免疫グロブリン結合タンパク質
JP2013226148A (ja) * 2008-08-11 2013-11-07 Emd Millipore Corp 改善された特異性を有する新規免疫グロブリン結合タンパク質
JP2016121152A (ja) * 2008-08-11 2016-07-07 イー・エム・デイー・ミリポア・コーポレイシヨン 改善された特異性を有する新規免疫グロブリン結合タンパク質
JP2013534532A (ja) * 2010-07-02 2013-09-05 ザ・ユニバーシティ・オブ・シカゴ プロテインＡ（ＳｐＡ）変種に関連する組成物および方法

Also Published As

Publication number Publication date
EP2017343A3 (en) 2009-01-28
AU777005B2 (en) 2004-09-30
EP1181052A1 (en) 2002-02-27
EP2017343A2 (en) 2009-01-21
US20060205016A1 (en) 2006-09-14
EP1181052A4 (en) 2004-08-11
AU5019100A (en) 2000-12-05
WO2000069457A1 (en) 2000-11-23
CA2374013A1 (en) 2000-11-23

Similar Documents

Publication Publication Date Title
Deacy et al. Superantigen recognition and interactions: functions, mechanisms and applications
Roben et al. VH3 family antibodies bind domain D of staphylococcal protein A.
CN111333729B (zh) 抗b细胞成熟抗原的纳米抗体及应用
JP2002544237A (ja) 望ましい活性を有するプロテインａに基づく結合ドメイン
Kindt The antibody enigma
CN109937212B (zh) B7-h3抗体、其抗原结合片段及其医药用途
TWI840399B (zh) 結合人il-4r的抗體、其抗原結合片段及其醫藥用途
Zouali B-cell superantigens: implications for selection of the human antibody repertoire
Potter et al. Staphylococcal protein A simultaneously interacts with framework region 1, complementarity-determining region 2, and framework region 3 on human VH3-encoded Igs
Sasano et al. Molecular selection of human antibodies with an unconventional bacterial B cell antigen.
Scott et al. Clonal characterization of the human IgG antibody repertoire to Haemophilus influenzae type b polysaccharide. III. A single VKII gene and one of several JK genes are joined by an invariant arginine to form the most common L chain V region.
Buonpane et al. Characterization of T cell receptors engineered for high affinity against toxic shock syndrome toxin-1
Flicker et al. Spatial clustering of the IgE epitopes on the major timothy grass pollen allergen Phl p 1: importance for allergenic activity
RU2712251C1 (ru) Гуманизированные антитела против участка бета цепи 9-го семейства TRBV9 TKP человека, и способы их применения
Gu et al. Defining the structural basis for human alloantibody binding to human leukocyte antigen allele HLA-A* 11: 01
CA2471570A1 (en) Focussed antibody technology
EP3083679B1 (en) Antibodies directed against the lukgh (lukab) toxin of staphylococcus aureus and antibody sequences
CN107849123A (zh) 抗替代性轻链抗体
Cary et al. Characterization of superantigen-induced clonal deletion with a novel clan III-restricted avian monoclonal antibody: exploiting evolutionary distance to create antibodies specific for a conserved VH region surface
WO2022037527A1 (zh) 结合bcma的单可变结构域及抗原结合分子
US7163686B1 (en) Protein A based binding domains with desirable activities
Lucas et al. Variable region sequences of a protective human monoclonal antibody specific for the Haemophilus influenzae type b capsular polysaccharide
Harmer et al. A human monoclonal antiphospholipid antibody that is representative of serum antibodies and is germline encoded
Robertson et al. Patterns of heavy and light chain utilization in the antibody response to single-stranded bacterial DNA in normal human subjects and patients with systemic lupus erythematosus
Leucht et al. The B cell superantigen-like interaction of intravenous immunoglobin (IVIG) with Fab fragments of VH 3-23 and 3-30/3-30.5 germline gene origin cloned from a patient with Kawasaki disease is enhanced after IVIG therapy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070515

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070515

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20081110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20081110

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100316

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100817